PMID- 25306426
OWN - NLM
STAT- MEDLINE
DCOM- 20160603
LR  - 20150821
IS  - 1532-1983 (Electronic)
IS  - 0261-5614 (Linking)
VI  - 34
IP  - 5
DP  - 2015 Oct
TI  - Effect of niacin on lipids and glucose in patients with type 2 diabetes: A 
      meta-analysis of randomized, controlled clinical trials.
PG  - 838-44
LID - S0261-5614(14)00247-7 [pii]
LID - 10.1016/j.clnu.2014.09.019 [doi]
AB  - BACKGROUND & AIMS: This study aims to conduct a meta-analysis to evaluate the 
      effects of niacin on serum lipids and glucose in patients with type 2 diabetes 
      mellitus (T2DM). METHODS: A comprehensive literature search in Medline, Scopus, 
      AMED, Cochrane and Clinical trial registry databases was performed to identify 
      randomized controlled trials investigating the effect of niacin on serum HDL 
      cholesterol (HDL-c), LDL cholesterol (LDL-c), triglycerides (TG) and fasting 
      plasma glucose (FPG). Pooled effects were measured by weighted mean difference 
      (WMD) using fixed-effects or random-effects models. Quality assessment, and 
      subgroup, meta-regression and sensitivity analyses were conducted using standard 
      methods. Inter-study heterogeneity was assessed and quantified. RESULTS: The 
      estimated pooled mean changes (95% confidence interval) with niacin were 0.27 
      (95% CI: 0.24 to 0.30; P < 0.001) mmol/L for HDL-c, -0.250 (95% CI: -0.47 to 
      -0.03; P < 0.05) mmol/L for LDL-c and -0.39 (95% CI: -0.43 to -0.34; P < 0.001) 
      mmol/L for TG compared with controls. There was a significant heterogeneity for 
      the impact of niacin on LDL-c and FPG. Subgroup analyses revealed a significant 
      increase in FPG 0.085 (95% CI: 0.029 to 0.141; P < 0.05) mmol/L compared with 
      controls in patients with long term treatment. Our analysis also showed the 
      absence of publication bias and any dose-response relations between niacin and 
      effect size. CONCLUSIONS: Analysis of the results showed that niacin alone or in 
      combination significantly improved lipid abnormalities in patients with TDM, but 
      requires monitoring of glucose in long term treatment.
CI  - Copyright (c) 2014 Elsevier Ltd and European Society for Clinical Nutrition and 
      Metabolism. All rights reserved.
FAU - Ding, Yi
AU  - Ding Y
AD  - Department of Pharmacy, Xijing Hospital, The Fourth Military Medical University, 
      Xi'an, Shaanxi, China.
FAU - Li, YuWen
AU  - Li Y
AD  - Department of Pharmacy, Xijing Hospital, The Fourth Military Medical University, 
      Xi'an, Shaanxi, China. Electronic address: liyuwenzs@gmail.com.
FAU - Wen, AiDong
AU  - Wen A
AD  - Department of Pharmacy, Xijing Hospital, The Fourth Military Medical University, 
      Xi'an, Shaanxi, China. Electronic address: adwen-2004@hotmail.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20140928
PL  - England
TA  - Clin Nutr
JT  - Clinical nutrition (Edinburgh, Scotland)
JID - 8309603
RN  - 0 (Blood Glucose)
RN  - 0 (Cholesterol, HDL)
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Triglycerides)
RN  - 2679MF687A (Niacin)
SB  - IM
MH  - Blood Glucose/*metabolism
MH  - Cholesterol, HDL/blood
MH  - Cholesterol, LDL/blood
MH  - Databases, Factual
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy
MH  - Fasting
MH  - Humans
MH  - Niacin/*administration & dosage
MH  - Randomized Controlled Trials as Topic
MH  - Risk Assessment
MH  - Triglycerides/blood
OTO - NOTNLM
OT  - Clinical trial
OT  - Meta-analysis
OT  - Niacin
OT  - Type 2 diabetes
EDAT- 2014/10/13 06:00
MHDA- 2016/06/04 06:00
CRDT- 2014/10/13 06:00
PHST- 2014/07/04 00:00 [received]
PHST- 2014/09/16 00:00 [revised]
PHST- 2014/09/18 00:00 [accepted]
PHST- 2014/10/13 06:00 [entrez]
PHST- 2014/10/13 06:00 [pubmed]
PHST- 2016/06/04 06:00 [medline]
AID - S0261-5614(14)00247-7 [pii]
AID - 10.1016/j.clnu.2014.09.019 [doi]
PST - ppublish
SO  - Clin Nutr. 2015 Oct;34(5):838-44. doi: 10.1016/j.clnu.2014.09.019. Epub 2014 Sep 
      28.